Core Viewpoint - Junshi Biosciences is actively developing a monkeypox recombinant protein vaccine in collaboration with several prestigious institutions, indicating a strategic focus on innovative vaccine development and expanding its product pipeline [2][3]. Group 1: Company Developments - On October 27, 2023, Junshi Biosciences announced a partnership with Peking University, the Institute of Microbiology of the Chinese Academy of Sciences, Shanxi Higher Innovation Research Institute, and Beihang University to jointly develop a monkeypox recombinant protein vaccine [2]. - The company’s subsidiary, Junshi Biotech, is involved in the development of various vaccine-related products, including monkeypox and Zika vaccines, which are currently in the preclinical development stage [2]. - Junshi Biosciences has a complete industry chain capability from drug discovery and development to global clinical research, large-scale production, and commercialization, aiming to become a leading innovative pharmaceutical company [3]. Group 2: Product Pipeline and Innovations - The core product, Toripalimab, is the first domestically approved PD-1 monoclonal antibody in China, with 11 approved indications and one supplemental NDA under review, showcasing its market potential [3]. - The company’s self-developed Tifcemalimab is the first anti-tumor anti-BTLA monoclonal antibody to enter clinical development, with ongoing Phase III registration clinical studies and multiple Phase Ib/II studies in progress [3]. - Junshi Biosciences is exploring early-stage pipelines, with several products expected to initiate key registration clinical trials by 2025 [3]. Group 3: Financial Performance - For the period from January to September 2025, Junshi Biosciences reported revenue of 1.806 billion yuan, a year-on-year increase of 42.06%, while the net profit attributable to shareholders was -596 million yuan, reflecting a 35.72% year-on-year growth [9]. - The company’s main business revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services and others [9]. Group 4: Market Position and Shareholder Information - As of September 30, 2025, Junshi Biosciences had 35,900 shareholders, an increase of 15.17% from the previous period, with an average of 21,361 circulating shares per person, a decrease of 12.96% [9]. - The company is categorized under the pharmaceutical and biological industry, specifically in the bioproducts sector, and is involved in various concept sectors including monkeypox, exclusive drugs, and biomedicine [9].

Report Summary 1. Report Industry Investment Rating No information provided in the given content. 2. Core View of the Report The marginal driving force of stock index futures is limited, and it remains in a volatile pattern. On January 28, the monthly contracts of the four major stock index futures showed mixed gains and losses. The total trading volume of stock index futures declined on the trading day, indicating a cooling of investors' trading enthusiasm. The total positions of IF and IH increased, while those of IC and IM decreased [1][2]. 3. Summary by Related Catalogs 3.1. Stock Index Futures Data Tracking - **Closing Prices and Price Changes**: On January 28, IF rose 0.08%, IH fell 0.03%, IC rose 0.66%, and IM rose 0.22%. The closing prices and price - change percentages of various contracts of IF, IH, IC, and IM are detailed in the table [1]. - **Trading Volume and Position Changes**: The total trading volume of IF, IH, IC, and IM decreased, with decreases of 62 lots, 4488 lots, 40713 lots, and 68320 lots respectively. The total positions of IF and IH increased by 15622 lots and 3905 lots respectively, while those of IC and IM decreased by 904 lots and 15637 lots respectively [1][2]. - **Basis**: The basis data of IF, IH, IC, and IM are presented, showing the differences between futures prices and spot prices [1]. - **Top 20 Member Position Changes**: The changes in long and short positions of the top 20 members of IF, IH, IC, and IM contracts are provided, including net changes in some contracts [5]. 3.2. Trend Intensity The trend intensity of IF and IH is 1, and that of IC and IM is also 1. The trend intensity ranges from - 2 to 2, with - 2 being the most bearish and 2 being the most bullish [6]. 3.3. Important Drivers - **Quantitative Fund News**: There are rumors that regulatory authorities plan to implement the 'T + 3' system for the program trading of major quantitative funds, but many billion - level quantitative private equity managers said they have not received relevant requirements [6]. - **Fed Policy Expectations**: As the expectation that BlackRock's chief investment officer Rick Rieder may replace Powell grows, some futures and options traders are betting on the Fed to turn dovish. Rieder said earlier this month that the Fed's benchmark interest rate should be lowered from the current 3.5% - 3.75% range to 3% [6]. - **Stock Market Performance**: The A - share market showed narrow fluctuations. The Shanghai Composite Index rose 0.27%, the Shenzhen Component Index rose 0.09%, and the ChiNext Index fell 0.57%. The turnover of A - shares reached 2.99 trillion yuan. The Hang Seng Index rose 2.58%, reaching a 4 - and - a - half - year high [6][7].

Group 1 - The biovaccine sector saw an increase of 2.98%, ranking 9th among concept sectors, with 45 stocks rising, including Hualan Vaccine and Jindike, which hit the 20% limit up [1] - Leading stocks in the biovaccine sector included Zhifei Biological, Dongfang Biological, and CanSino, which rose by 14.87%, 12.36%, and 11.67% respectively [1] - The sector experienced a net inflow of 1.305 billion yuan from main funds, with 36 stocks receiving net inflows, and five stocks exceeding 100 million yuan in net inflow [2] Group 2 - The top net inflow stock was Watson Bio, with a net inflow of 297 million yuan, followed by Zhifei Biological, Junshi Biological, and Hualan Vaccine with net inflows of 261 million yuan, 169 million yuan, and 143 million yuan respectively [2] - The net inflow ratios for Hualan Vaccine, Junshi Biological, and Keqian Biological were 23.86%, 15.20%, and 14.32% respectively, indicating strong investor interest [3] - The biovaccine sector's performance was contrasted by declines in other sectors, such as military information technology and commercial aerospace, which fell by 4.70% and 3.56% respectively [2]

Market Overview - The A-share market experienced a narrow fluctuation with over 3,700 stocks in the red, while the Shanghai Composite Index slightly increased by 0.12% and the Shenzhen Component Index and ChiNext Index fell by 0.74% and 0.86% respectively [1] - The total trading volume in the Shanghai and Shenzhen markets reached approximately 2.26 trillion yuan [1] Sector Performance - Sectors such as semiconductors, retail, liquor, and real estate saw declines, while insurance, oil, non-ferrous metals, coal, and brokerage sectors showed gains [1] - Gold and biopharmaceutical concepts were active in the market [1] Short-term Market Outlook - According to Zhongyin Securities, the market is currently in a high-level fluctuation phase with increasing structural differentiation, driven by expectations for domestic demand expansion policies and supply-side policies to curb industry "involution" [1] - There is a caution regarding the impact of short-term regulatory easing on the marginal increase of ETF and leveraged funds on the market [1] - The market may enter a phase of oscillation and speculation before the holiday, with a focus on performance-driven stocks [1] Industry Insights - The non-ferrous metals industry is expected to benefit from dual drivers of industrial trends and financial attributes by 2026 [1] - The anticipated interest rate cuts by the Federal Reserve and risk aversion are expected to enhance the industry's valuation [1] - In the context of Sino-US competition, strategic metals such as rare earths, tungsten, and antimony may see a revaluation of their strategic value [1] - In the short term, the upward slope of the industry may slow down, with a focus on industrial metals and precious metals that have performance support [1]

Market Overview - The A-share market experienced a narrow fluctuation with over 3,700 stocks in the red, while the Shanghai Composite Index slightly increased by 0.12% and the Shenzhen Component Index and ChiNext Index decreased by 0.74% and 0.86% respectively [1] - The total trading volume in the Shanghai and Shenzhen markets reached approximately 2.26 trillion yuan [1] Sector Performance - Sectors such as semiconductors, retail, liquor, and real estate saw declines, while insurance, oil, non-ferrous metals, coal, and brokerage sectors showed gains [1] - Gold and biopharmaceutical concepts were notably active in the market [1] Short-term Market Outlook - According to Zhongyin Securities, the market is currently in a high-level fluctuation phase with increasing structural differentiation, driven by expectations for domestic demand expansion policies and supply-side policies aimed at curbing industry "involution" [1] - There is an anticipation of a phase of oscillation and speculation in the market before the holiday, with a focus on performance-driven stocks [1] Industry Insights - The non-ferrous metals industry is expected to benefit from dual drivers of industrial trends and financial attributes by 2026, with expectations of a Federal Reserve interest rate cut and risk aversion boosting industry valuations [1] - In the context of Sino-US competition, strategic metals such as rare earths, tungsten, and antimony may see a revaluation of their strategic value [1] - In the short term, the upward slope of the industry may slow down, with a focus on industrial metals and precious metals that have performance support [1]

Group 1 - The biovaccine sector experienced a decline of 0.30% as of the market close on November 28, ranking among the top losers in concept sectors [1] - Within the biovaccine sector, notable declines were observed in Hualan Biological, Jindike, and *ST Wanfang, while 24 stocks saw price increases, with Kanghua Biological, Shenzhou Cell, and Lanxiao Technology leading the gains at 2.10%, 1.66%, and 1.66% respectively [1][2] - The biovaccine sector faced a net outflow of 499 million yuan from major funds today, with 41 stocks experiencing net outflows, and 19 stocks seeing outflows exceeding 10 million yuan [2] Group 2 - The top three stocks with the highest net outflows in the biovaccine sector were Wantai Biological (-2.18%), *ST Wanfang (-4.11%), and Jindike (-6.55%), with net outflows of 68.27 million yuan, 41.63 million yuan, and 34.53 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflows included Dezhan Health, New Source, and Meihua Biological, with net inflows of 12.45 million yuan, 5.47 million yuan, and 4.02 million yuan respectively [4]

Market Overview - On November 25, A-shares saw all major indices rise, with the Shanghai Composite Index increasing by 0.87% to 3870.02 points, the Shenzhen Component Index rising by 1.53% to 12777.31 points, and the ChiNext Index gaining 1.77% to 2980.93 points. The total trading volume in the Shanghai and Shenzhen markets reached 182.64 billion yuan, an increase of 8.59 billion yuan from the previous day [1] AI Industry - The AI industry chain stocks experienced a collective surge, with significant gains in CPO and PCB concepts. Notable stocks included Dekoli, Guangku Technology, and Changguang Huaxin, all hitting the 20% limit up [1][3] - Google recently launched its AI model Gemini 3, aiming to double its computing power every six months, with a long-term goal of achieving a 1000-fold increase in capacity over the next 4 to 5 years [5] - Amazon announced a $50 billion investment to expand its AWS AI and high-performance computing capabilities for U.S. government clients, enhancing access to various AI services [5] Consumer Electronics - The consumer electronics sector saw a significant rise, particularly in Apple-related stocks. Stocks like Lingyun Optics rose over 10%, while Dongshan Precision and Shenzhen South Circuit increased by over 7% [8] - Counterpoint Research indicated that by October 2025, iPhones are expected to account for 25% of smartphone sales in China, with a 37% year-on-year growth driven by the strong performance of the iPhone 17 series [10] - Recent reports suggest that Apple has made breakthroughs in developing a foldable iPhone, addressing previous concerns about creases, which could enhance its market appeal [8][10] Vaccine Sector - The biopharmaceutical vaccine sector showed strong performance, with stocks like Jindike hitting the 20% limit up and Hualan Vaccine rising over 10% [12] - There has been a notable increase in demand for flu medications, with sales of antiviral drugs like Oseltamivir surging by 237% in the past week, indicating a rise in respiratory disease cases [14]

Market Overview - On November 25, A-shares saw all major indices rise, with the Shanghai Composite Index increasing by 0.87% to 3870.02 points and the ChiNext Index rising by 1.77% to 2980.93 points, while the total trading volume in the Shanghai and Shenzhen markets reached 182.64 billion yuan, an increase of 85.9 billion yuan from the previous day [2] AI Industry - The AI industry chain stocks experienced a significant surge, with companies like Dekoli, Guangku Technology, and Changguang Huaxin hitting the 20% limit up [3][5] - The CPO concept stocks also saw strong performance, with notable gains from companies such as Changxin Bochuang and Juguang Technology, which rose nearly 14% [3] PCB Sector - The PCB concept stocks strengthened, with companies like Huhua Technology and Bojie Shares reaching the limit up, while Jingwang Electronics and Shengyi Technology increased by over 6% [5] Consumer Electronics - The consumer electronics sector saw substantial gains, particularly in Apple-related stocks, with Lingyun Technology rising over 10% and Dongshan Precision increasing by 7.68% [7][8] - Reports indicate that Apple has made breakthroughs in developing a foldable iPhone, addressing previous concerns about creases, which could enhance the market appeal of the upcoming model [7] Vaccine Sector - The vaccine concept stocks surged, with Jindike hitting the 20% limit up and Hualan Vaccine increasing by over 10% [12] - The demand for flu medications has risen sharply, with sales of Oseltamivir increasing by 237% in the past week, indicating a growing need for respiratory system medications due to the flu outbreak [11]

Market Overview - On November 25, A-shares saw a broad increase, with the Shanghai Composite Index rising over 1% at one point, and the ChiNext Index gaining over 3% during the session [1][2] - The total trading volume in the Shanghai and Shenzhen markets reached 18,264 billion yuan, an increase of 859 billion yuan compared to the previous day [2] AI Industry Chain - Stocks in the AI industry chain experienced a collective surge, with significant gains in CPO and PCB concepts [3][4] - Notable stocks included Dekoli, Guangku Technology, and Changguang Huaxin, all hitting the 20% limit up [4][5] - The demand for computing power driven by AI remains robust, with institutions optimistic about the long-term outlook for the AI sector [7] Consumer Electronics - The consumer electronics sector saw a substantial rise, particularly driven by Apple-related stocks [8][9] - Stocks such as Lingyun Technology and Dongshan Precision rose over 10%, while others like Shenzhen South Circuit and Luxshare Precision increased by more than 7% [9][10] - Apple is reportedly making breakthroughs in developing a foldable iPhone, which could enhance its market appeal [11] - iPhone sales in China are projected to grow by 37% year-on-year, driven by strong performance from the iPhone 17 series [12] Vaccine Sector - The biopharmaceutical sector, particularly vaccine stocks, showed significant upward movement, with stocks like Jindike and Hualan Vaccine hitting the 20% limit up [13][14] - The demand for flu medications has surged, with sales of antiviral drugs increasing significantly due to rising flu activity [16][17]

Core Viewpoint - TianTan Biological experienced a sharp increase in stock price, reaching the daily limit, while other companies in the sector such as Keta Bio, Nanmo Bio, and Sairun Bio saw their stock prices rise by over 10% [1] Company Performance - TianTan Biological's stock price hit the daily limit, indicating strong market interest and confidence in the company [1] - Keta Bio, Nanmo Bio, and Sairun Bio also showed significant gains, with stock prices increasing by more than 10%, reflecting positive sentiment in the biotechnology sector [1] - Watson Bio and Anxu Bio, among others, followed suit with notable increases in their stock prices, suggesting a broader rally in the biotechnology industry [1]